Tracking the NAMS expected move helps you see how far NewAmsterdam Pharma Company NV's options market is pricing the stock to travel over a given period — whether that's the next day, week, or earnings cycle. NewAmsterdam Pharma Company NV's expected move is derived directly from option premiums and gives you an objective range to plan trades, set strikes, and manage risk. Use our scanner to monitor the NAMS expected move for this week's options, in real time.
The expected move is typically calculated from at-the-money straddle prices (or a blend of straddles and strangles) and represents roughly a one-standard-deviation range over the chosen timeframe. For NAMS, comparing the implied expected move to actual realized moves over similar windows tells you whether the options market has historically overestimated or underestimated volatility. The NAMS expected move for this week's options pricing is especially useful for short-dated traders, earnings players, and anyone selling premium who needs to know where the market thinks NewAmsterdam Pharma Company NV is unlikely to go.
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Iron condors, weekly premium sales, directional swing trades — they all live or die by where the market thinks the stock won't go. Our scanner tracks the NAMS expected move across every expiration, benchmarks it against realized moves, and shows you when implied ranges are out of line with history. The NewAmsterdam Pharma Company NV expected move for this week's options is the fastest read on short-term risk, which gives you a quick way to interpret what the options market thinks about NAMS.
